Artivion, Inc. (NYSE:AORT) Shares Sold by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System lowered its holdings in shares of Artivion, Inc. (NYSE:AORT) by 8.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,200 shares of the company’s stock after selling 1,700 shares during the period. Louisiana State Employees Retirement System’s holdings in Artivion were worth $484,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in AORT. Allspring Global Investments Holdings LLC raised its position in shares of Artivion by 291.3% in the first quarter. Allspring Global Investments Holdings LLC now owns 5,580 shares of the company’s stock valued at $118,000 after buying an additional 4,154 shares during the last quarter. BNP Paribas Financial Markets raised its stake in Artivion by 79.3% during the first quarter. BNP Paribas Financial Markets now owns 19,706 shares of the company’s stock worth $417,000 after purchasing an additional 8,715 shares during the period. Texas Permanent School Fund Corp boosted its holdings in shares of Artivion by 2.0% in the 1st quarter. Texas Permanent School Fund Corp now owns 34,129 shares of the company’s stock valued at $722,000 after purchasing an additional 677 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Artivion by 26.9% during the 1st quarter. Russell Investments Group Ltd. now owns 15,187 shares of the company’s stock worth $321,000 after buying an additional 3,217 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System increased its holdings in shares of Artivion by 70.5% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 19,197 shares of the company’s stock worth $406,000 after buying an additional 7,940 shares during the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Price Performance

Shares of NYSE AORT opened at $27.91 on Wednesday. Artivion, Inc. has a 1-year low of $13.18 and a 1-year high of $29.24. The company has a debt-to-equity ratio of 1.07, a current ratio of 5.63 and a quick ratio of 4.04. The business’s fifty day moving average price is $26.06 and its two-hundred day moving average price is $25.00. The firm has a market capitalization of $1.17 billion, a PE ratio of -132.90 and a beta of 1.75.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.04. The company had revenue of $98.02 million for the quarter, compared to analyst estimates of $97.70 million. Artivion had a positive return on equity of 3.81% and a negative net margin of 2.22%. On average, research analysts expect that Artivion, Inc. will post 0.2 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on AORT shares. Stifel Nicolaus increased their target price on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, September 13th. Needham & Company LLC reissued a “buy” rating and set a $30.00 target price on shares of Artivion in a research report on Friday, September 27th. JMP Securities assumed coverage on shares of Artivion in a research report on Wednesday, October 23rd. They set an “outperform” rating and a $33.00 target price for the company. Finally, Oppenheimer upped their price target on Artivion from $25.00 to $30.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $30.60.

Insider Buying and Selling

In related news, SVP Jean F. Holloway sold 3,167 shares of Artivion stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $26.55, for a total transaction of $84,083.85. Following the transaction, the senior vice president now directly owns 161,932 shares of the company’s stock, valued at $4,299,294.60. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, SVP Jean F. Holloway sold 3,167 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $26.55, for a total transaction of $84,083.85. Following the completion of the sale, the senior vice president now directly owns 161,932 shares of the company’s stock, valued at $4,299,294.60. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Amy Horton sold 12,430 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total value of $325,417.40. Following the sale, the chief accounting officer now directly owns 139,989 shares of the company’s stock, valued at $3,664,912.02. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 37,109 shares of company stock valued at $951,935 over the last three months. Company insiders own 8.10% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.